Fate Therapeutics (FATE) Short term Debt (2012 - 2019)

Fate Therapeutics has reported Short term Debt for 8 years, with the latest figure at $13.9 million in Q3 2019.

• For the quarter ending Q3 2019, Short term Debt rose 326.84% year-over-year to $13.9 million; the trailing twelve-month figure through Sep 2019 stood at $13.9 million (up 326.84% YoY), and the FY2018 full-year result was $2.4 million, changed N/A from the prior year.
• Short term Debt for Q3 2019 stood at $13.9 million, up from $5.4 million in the prior quarter.
• The five-year high for Short term Debt was $13.9 million in Q3 2019, with the low at $758000.0 in Q1 2018.
• Historically, Short term Debt has averaged $5.9 million across 5 years, with a median of $6.0 million in 2015.
• Annual changes were most pronounced in 2015 — Short term Debt surged 962.85% — and 2018, when it slumped 90.05%.
• Fate Therapeutics' Short term Debt stood at $7.6 million in 2015, then climbed by 8.44% to $8.2 million in 2016, then slipped by 6.93% to $7.6 million in 2017, then tumbled by 68.01% to $2.4 million in 2018, then jumped by 471.45% to $13.9 million in 2019.
• The last three Short term Debt figures came in at $13.9 million (Q3 2019), $5.4 million (Q2 2019), and $3.9 million (Q1 2019), per Business Quant data.